Advertisement

Topics

CSL Behring Canada Company Profile

19:14 EST 22nd November 2017 | BioPortfolio

Berinert is the only HAE therapy available in Canada. It offers over 30 years of international clinical use experience with more than 400,000 treatments given in Germany, Austria, Switzerland, Japan, Australia and several other countries where it is manufactured and sold by CSL Behring.


News Articles [351 Associated News Articles listed on BioPortfolio]

CSL Behring to acquire Calimmune for $91M

Global biotherapeutics provider CSL Behring has agreed to acquire Calimmune, a biotechnology company focused on the development of ex vivo hematopoietic stem cell (HSC) gene therapy with R&D fa...

FDA grants approval to CSL Behring's hereditary angioedema drug

CSL Behring's Haegarda, or human C1 esterase inhibitor, subcutaneous injection has been approved by the FDA to prevent heredi -More- 

CSL Behring to acquire stem cell therapy biotech firm

CSL Behring, a subsidiary of Australia’s CSL Limited, has agreed to acquire Calimmune, a US biotechnology…

CSL Behring acquires Tucson biotech for $91 millionabout 1 hour ago

Biotherapeutics company CSL Behring in King of Prussia will buy Calimmune Inc. for at least $91 million to add an early-stage stem-cell gene therapy for sickle cell disease to its product pipelin...

CSL Behring pays $91M upfront for early stage gene therapy

Purchase of a Tucson biotech brings CSL Behring into the stem cell gene therapy arena.

CSL Behring to buy US biotechnology firm Calimmune

CSL Behring, the US subsidiary of Australia-based CSL has agreed to acquire Calimmune, an American biotechnology company focused on developing ex vivo hematopoietic stem cell (HSC) gene therapy.

CSL Behring receives Orphan Drug exclusivity for Haegarda

CSL Behring announced that the FDA has granted the company seven years of orphan drug exclusivity for Haegarda (C1 Esterase Inhibitor Subcutaneous [Human]), the first and only subcutaneous treatment...

CSL Behring buys Calimmune for $91mm up front plus $325mm in earn-outs

CSL Behring paid $91mm up front to acquire privately held gene therapy company Calimmune Inc. The deal also includes up to $325mm in performance-based milestones over a period of at least eight years....

PubMed Articles [385 Associated PubMed Articles listed on BioPortfolio]

Ehrlich and Von Behring.

Radiation oncology in Canada.

In this article we provide an overview of the Canadian healthcare system and the cancer care system in Canada as it pertains to the governance, funding and delivery of radiotherapy programmes. We also...

In Conversation with Leslee Thompson.

In healthcare, no organization was as synonymous with quality and safety as Accreditation Canada, an independent agency established in 1958 to verify and certify that healthcare service providers met ...

Commentary - Food for thought on food environments in Canada.

Talking about food.

Clinical Trials [396 Associated Clinical Trials listed on BioPortfolio]

A Canadian Study to Assess the Safety of Humate-P® Ivr (Infusion Volume Reduced)

As part of CSL Behring Canada's continued commitment to ensuring the safety of the new low volume preparation of Humate-P®, CSL Behring Canada proposes to conduct a prospective, multi-cen...

Healthier Living Canada

This study will evaluate the effectiveness of an online Chronic Disease Self-Management Program for participants in Canada living with chronic health conditions. This pilot will look for i...

The Effect of Human Albumin on Coagulation Competence and Hemorrhage

In a randomized clinical trial, the purpose is to investigate if perioperative coagulation and hemorrhage is influenced by colloid or crystalloid.

Effectiveness of Intravenous Immunoglobulins (IVIG) in Toxic Shock Syndromes in Children

IGHN2 is an international, multicenter, double blind, randomized controlled trial aimed at assessing the efficacy on organ dysfunctions of Intravenous Immunoglobulins (IVIG) treatment in t...

Distribution of Risk Factors in Ocular Hypertension and Open-Angle Glaucoma Patients in Canada

This descriptive, non-interventional study will collect information on the presence of risk factors in newly diagnosed OH and OAG patients in Canada.

Companies [745 Associated Companies listed on BioPortfolio]

CSL Behring Canada

Berinert is the only HAE therapy available in Canada. It offers over 30 years of international clinical use experience with more than 400,000 treatments given in Germany, Austria, Switzerland, Japan, ...

Dade Behring's chemistry

With 2005 revenue of nearly $1.7 billion, Dade Behring is the world's largest company dedicated solely to clinical diagnostics. It offers a wide range of products, systems and services designed to mee...

CSL Behring

CSL Behring is a leader in the plasma protein therapeutics industry. Committed to saving lives and improving the quality of life for people with rare and serious diseases, the com...

ZLB Behring LLC

ZLB Behring is one of the world’s leading pharmaceutical companies specializing in the manufacture of plasma products. Its comprehensive line of therapies include products for the treatment of hemop...

ZLB Behring

ZLB Behring is one of the world’s leading pharmaceutical companies specializing in the manufacture of plasma products. Its comprehensive line of therapies include products for the treatment of hemop...

More Information about "CSL Behring Canada" on BioPortfolio

We have published hundreds of CSL Behring Canada news stories on BioPortfolio along with dozens of CSL Behring Canada Clinical Trials and PubMed Articles about CSL Behring Canada for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of CSL Behring Canada Companies in our database. You can also find out about relevant CSL Behring Canada Drugs and Medications on this site too.

Quick Search
Advertisement
 

Corporate Database Quicklinks



Searches Linking to this Company Record